ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Ligand-Driven Annular-Epitaxial Growth of CuS-Au Heterostructures as Trinity Plasmonic Nanozyme for Multimode Diagnosis of Pathogenic Bacteria.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Transport-Reaction-Signal Coupling in Lateral Flow Assays for Next-Generation Point-of-Care Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A Review of SERS-Based Bacterial Detection from Nanomaterials to Integrated Clinical Platforms.Biosensors · 2026Review
- Metal nanozyme sensors with different modes: biomedical applications and research advances.Frontiers in bioengineering and biotechnology · 2026Review
- Charge-mediated directed assembly of Pt nanoshell on PDA: colorimetric-catalytic co-enhanced lateral flow immunoassay for point-of-care testing.Journal of nanobiotechnology · 2025Article
- An Interpretable SERS-AI Platform for Rapid and Quantitative Diagnosis of Polymicrobial UTIs: Powered by Positively Charged Plasmonic Nanoparticles and Attention-Based Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An integrated multi-mode detection platform based on CRISPR/Cas 12a and aptamers for ultra-sensitive identification of sulfamethazine and genes associated with sulfonamide resistance.Journal of nanobiotechnology · 2025Article
- Ligand-Driven Annular-Epitaxial Growth of CuS-Au Heterostructures as Trinity Plasmonic Nanozyme for Multimode Diagnosis of Pathogenic Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study presents a novel method to control the site-selective growth of Au nanostars on CuS nanodisc substrate, it indicates that the surfactant ligands play a key role in the architecture control, only CTAC and homologous series with appropriate affinity to CuS can direct the annular-epitaxial growth of Au nanoparticles on the CuS, which demonstrates superior peroxidase (POD)-mimic and SERS activity. Mechanistic studies indicate that plasmon-enhanced catalytic and SERS activity can be attributed to the spatially separated CuS-Au heterostructure, which supports the light-triggered hot electron-hole pairs production and localized surface plasmon resonance hotspots. For practical biosensing, the CuS-Au heterostructures assembled lateral flow assay (LFA) was used for SERS/catalytic colorimetric/photothermal three-mode detection of Streptococcus pneumoniae and Klebsiella pneumoniae, with visually colorimetric mode at 103 CFU/mL and quantitative SERS/photothermal modes at 2-10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.